Lazard Asset Management LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 24.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,904,438 shares of the company’s stock after selling 2,229,468 shares during the period. Lazard Asset Management LLC owned 1.41% of Zoetis worth $430,697,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN increased its stake in Zoetis by 8.2% during the second quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock worth $319,008,000 after acquiring an additional 389,260 shares during the last quarter. Gladstone Capital Management LLP bought a new stake in Zoetis during the second quarter worth approximately $3,134,000. Swiss National Bank increased its stake in Zoetis by 8.1% during the second quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock worth $112,058,000 after acquiring an additional 133,900 shares during the last quarter. Harbour Capital Advisors LLC increased its stake in Zoetis by 19.8% during the first quarter. Harbour Capital Advisors LLC now owns 20,005 shares of the company’s stock worth $1,068,000 after acquiring an additional 3,300 shares during the last quarter. Finally, Hermes Investment Management Ltd. increased its stake in Zoetis by 80.3% during the second quarter. Hermes Investment Management Ltd. now owns 236,350 shares of the company’s stock worth $14,744,000 after acquiring an additional 105,276 shares during the last quarter. Institutional investors own 93.20% of the company’s stock.
Several equities research analysts have weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. Hilliard Lyons assumed coverage on Zoetis in a research note on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective on the stock. Credit Suisse Group boosted their price objective on Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 24th. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a research note on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $65.44.
Zoetis Inc. (ZTS) traded up 0.15% on Monday, hitting $65.30. The stock had a trading volume of 406,509 shares. The stock has a market cap of $31.94 billion, a PE ratio of 36.91 and a beta of 1.02. The firm’s 50 day moving average price is $62.29 and its 200-day moving average price is $59.39. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $65.83.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.49 EPS. On average, analysts forecast that Zoetis Inc. will post $2.34 EPS for the current year.
WARNING: This article was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/18/zoetis-inc-zts-shares-sold-by-lazard-asset-management-llc.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.